Anti-Idiotypic Antibody Development

The antigen-binding function of an antibody is mediated by its variable regions. In the case of IgG-class antibodies, the heavy-chain variable domain (VH) and light-chain variable domain (VL) fold together to form the complete antigen-binding pocket. Each variable domain contains three highly diverse complementarity-determining regions (CDR1, CDR2, and CDR3); thus, the six CDR sequences collectively define the antigen specificity and binding affinity of the antibody. Therapeutic antibody-based agents, such as antibody–drug conjugates (ADCs), utilize the intact antibody molecule as a targeting vehicle, relying on the variable-region CDRs to specifically recognize cell-surface target antigens on tumor cells, thereby enabling precise in vivo delivery of effector moieties for targeted therapy. Anti-idiotypic antibodies are a class of antibodies that specifically recognize the idiotope(s) of another antibody. Their recognized epitopes are primarily located within the CDR regions of the target antibody, but may also encompass conformational epitopes formed by the framework regions of the variable domains.

Leveraging our proprietary phage display technology platform, KMD Bioscience offers comprehensive, end-to-end anti-idiotypic antibody preparation services—from library construction through antibody screening and expression. Utilizing a variety of starting materials, including gene-synthesized templates, hybridoma cell lines, and peripheral blood lymphocytes, we are capable of constructing naive antibody libraries, semi-synthetic libraries, and fully synthetic phage-displayed antibody libraries. Our libraries achieve independent clone capacities of up to 1011, with functionally effective clone numbers reaching 1010, providing robust support for the screening and isolation of highly specific, high-affinity monoclonal anti-idiotypic antibodies. For high-affinity anti-idiotypic antibodies identified through screening, we amplify their encoding genes via PCR and clone them into our proprietary phagemid expression system. This system features multi-host expression adaptability and enables efficient, high-level production of anti-idiotypic antibodies in phage display, prokaryotic, and mammalian expression systems, flexibly accommodating the preparation requirements of diverse downstream applications.

I. Antigen-Neutralizing Type

II. Antigen-Neutralizing Type

III. Drug-Target Complex Type